Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “immunotherapy”

175 pharma patents match "immunotherapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 175
Index total 30,257
Page 5 / 8

Quick answer

This filtered view shows 175 pharmaceutical patents matching "immunotherapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

175 results for “immunotherapy” · 30,257 patents in full index Clear search

  1. US 10953047

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  2. US 10954304

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  3. US 10946045

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  4. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  5. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  6. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  7. US 10935554

    Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  8. US 10918666

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 16, 2021 · Expires Feb 11, 2041

    granted

  9. US 2021038684

    Compositions and Methods for Cancer Immunotherapy

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Feb 11, 2021 · Expires Feb 6, 2041

    granted

  10. US 10894044

    Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted

  11. US 10894063

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted

  12. US 10835595

    PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy

    Inovio Pharmaceuticals, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted

  13. US 10835604

    Biomaterials for combined radiotherapy and immunotherapy of cancer

    Northwestern University · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted

  14. US 10821163

    Process for the production of a DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted

  15. US 10815455

    Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

    Vaximm AG · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  16. US 10799567

    Yeast-based immunotherapy and type I interferon sensitivity

    The Regents of the University of Colorado · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  17. US 10722537

    Activation of resident memory T cells for cancer immunotherapy

    Regents of the University of Minnesota · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  18. US 10722523

    Chemoimmunotherapy for epithelial cancer

    The Regents of the University of California · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  19. US 10711312

    Methods for immunotherapy-based treatment and assessment of cancer

    The Regents of the University of California · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted

  20. US 10695372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted

  21. US 10676530

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  22. US 10653723

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 19, 2020 · Expires May 14, 2040

    granted

  23. US 10646517

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 12, 2020 · Expires May 7, 2040

    granted

  24. US 10639330

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.